Is Mabwell (Shanghai) Bioscience (SHSE:688062) Using Too Much Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to

Simply Wall StJul 16 21:28 ET

Express News | FDA Grants Orphan Drug Designation to 7MW3711

ReutersJul 16 10:00 ET

Express News | Mabwell Receives Nmpa Approval for Clinical Trial of Novel Nectin-4 Targeting ADC in Tnbc

ReutersJul 15 10:00 ET

Express News | FDA Grants Fast Track Designation to 9MW2821 for the Treatment of Patients With Locally Advanced or Metastatic Nectin-4 Positive Tnbc

ReutersJul 12 10:00 ET

Maiwei Biotech (688062.SH): Net loss of 206 million yuan in the first quarter

Gelonghui, April 29丨Maiwei Biotech (688062.SH) released its report for the first quarter of 2024, achieving operating income of 67.551 million yuan, an increase of 1572.42% over the previous year; net profit attributable to shareholders of listed companies - 206 million yuan, net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 218 million yuan, and basic earnings per share of 0.51 yuan.

Gelonghui FinanceApr 29 09:17 ET

With 42% Ownership, Mabwell (Shanghai) Bioscience Co., Ltd. (SHSE:688062) Insiders Have a Lot Riding on the Company's Future

Key Insights Insiders appear to have a vested interest in Mabwell (Shanghai) Bioscience's growth, as seen by their sizeable ownership A total of 6 investors have a majority stake in the company with

Simply Wall StApr 11 19:17 ET